ABSTRACT
This chapter describes trade name, classification, approved Indications for psychological disorders, available dosage forms, storage, and compatibility, usual dosage and administration, and clinically significant drug interactions of Triazolam. Safety and efficacy of triazolam pharmacotherapy for women who are breast-feeding and their neonates and infants have not been established. Triazolam is excreted in breast milk. Triazolam pharmacotherapy is restricted for the short-term symptomatic management of insomnia that impairs daytime functioning. Prescribe triazolam pharmacotherapy cautiously to patients who have respiratory dysfunction, including sleep apnea. Triazolam pharmacotherapy may adversely affect respiratory function among these patients. Concurrent alcohol use may increase the CNS depressant action of triazolam. The most common ADRs associated with triazolam pharmacotherapy are extensions of its pharmacologic actions and include dizziness, drowsiness, somnolence, incoordination, irritability, and nervousness. Signs and symptoms of triazolam overdosage generally are extensions of its pharmacological actions and include confusion, excessive drowsiness, incoordination, slurred speech, and, ultimately, coma.
